Inventiva climbs nearly 5% following the decision of the Data Monitoring Committee (DMC) to recommend continuation, without modification of the current protocol, of the Phase III NATiV3 clinical trial with lanifibranor in MASH/NASH.

This recommendation is based on a planned review of safety data, based on an unmasked review of data from over 900 randomized patients, which confirmed the good safety profile of lanifibranor.

The patient who experienced the adverse event of increased liver tests, reported as SUSAR, was clinically symptom-free throughout the observation period and made a full recovery," says Inventiva.

Copyright (c) 2024 CercleFinance.com. All rights reserved.